Kirenol
Cat. No. :YN482487
CAS No. :52659-56-0
Product Name: | Kirenol |
CAS NO.: | 52659-56-0 |
Chemical Name: | |
Synonyms: | |
Molecular Weight: | 338.48 |
Molecular Formula: | C₂₀H₃₄O₄ |
SMILES: | C[C@]([C@@](CC1)([H])[C@]2(C)CO)(C[C@H](O)C2)[C@@]3([H])C1=C[C@]([C@@H](O)CO)(C)CC3 |
Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |
Transportation: | Room temperature in continental US; may vary elsewhere. |
Description: | Kirenol possesses anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities. Kirenol is effective against gram-positive bacteria. Kirenol may be a potential immunosuppressant for the treatment for rheumatoid arthritis. Kirenol has significant potential for its discovery as a new lead compound for management of topical pain and inflammation. Kirenol is capable of inhibiting the differentiation and lipogenesis of 3T3-L1 adipocytes through the activation of the Wnt/β-catenin signaling pathway, suggesting its potential as natural anti-obesity agent. Kirenol can upregulate nuclear Annexin-1 which interacts with NF-κB to attenuate synovial inflammation of collagen-induced arthritis in rats. Kirenol can attenuate experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells. 8. Kirenol possesses antitumor action on human chronic myeloid leukemia K562 cells in vitro, it may have therapeutic potential for the treatment of cancer that deserves further investigation. 9. Kirenol is a potential candidate target for treating or preventing osteoporosis, it is capable of promoting osteoblast differentiation in MC3T3-E1 cells through activation of the BMP and Wnt/β-catenin signaling pathways. |
IC50&Target: | |
In Vitro: | |
In Vivo: | |
Clinical Trial: | |
Solvent & Solubility: | |
References: |
TELL : +86-020-82000279
Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.